Aspaveli
What Aspaveli is used for
Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Aspaveli
- Active substance
- pegcetacoplan
- Disease area
- Hemoglobinuria, Paroxysmal
- Medicine group
- Immunosuppressants
- ATC code
- L04AJ03
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB (publ)
- Authorised in the EU since
- 2021
Official information
In the USA
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Aspaveli used for?
Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
What is the active substance in Aspaveli?
Aspaveli contains pegcetacoplan.
Who makes Aspaveli?
The EU marketing authorisation holder is Swedish Orphan Biovitrum AB (publ).
Is Aspaveli an orphan medicine?
Yes. Aspaveli is designated an orphan medicine in the EU, for a rare disease (Hemoglobinuria, Paroxysmal).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU